Ascelia Pharma AB (ACE) Stock Statistics & Valuation Metrics

Ascelia Pharma AB has a market cap or net worth of kr86.53M. The enterprise value is kr371.41M.

Ascelia Pharma AB has 133,535,460 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascelia Pharma AB’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -73.35%.

The current PE Ratio of Ascelia Pharma AB is ―. Ascelia Pharma AB’s PEG ratio is 0.09.

In the last 12 months, Ascelia Pharma AB had revenue of 0.00 and earned -76.25M in profits. Earnings per share was -0.67.

In the last 12 months, operating cash flow was -71.19M and capital expenditures -57.00K, giving a free cash flow of -71.25M billion.

Ascelia Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Ascelia Pharma AB upcoming earnings date is Aug 20, 2026, Before Open (Confirmed).

Ascelia Pharma AB as a current ratio of 4.35, with Debt / Equity ratio of 0.83%

In the past 12 months, Ascelia Pharma AB has paid -468.00K in taxes.

Ascelia Pharma AB EV to EBITDA ratio is -4.32, with an EV/FCF ratio of -4.38.

Ascelia Pharma AB has kr33.89M in cash and marketable securities with kr689.00K in debt, giving a net cash position of kr33.20M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Ascelia Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―